Company intelligence / Profile preview

Galecto, Inc.

Ownership: Public · GLTO
Employees: ~5
Development stage: Other

Overview

Galecto has advanced multiple small molecule candidates into clinical development. GB1211, an oral galectin‑3 inhibitor, entered a Phase 2 trial in combination with pembrolizumab for metastatic melanoma and HNSCC in Q2 2024. BRM‑1420, a novel dual ENL-YEATS/FLT3 inhibitor for AML with activity in MLLr and NPM1c genetic subsets, was added to the pipeline in October 2024 based on promising preclinical data. Other programs include GB0139 for fibrotic lung disease and GB2064 targeting LOXL2[1][2][3].

Therapeutic areas: ImmunologyOncologyPulmonologyGastroenterology
Modalities: small molecules
Industry: Biotech

Partnerships

Investigator-led trial at Providence Portland Medical Center’s Earle A. Chiles Research Institute; no major pharma partnerships disclosed as of May 2025[2]

Beyond the preview

Go deeper on Galecto, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galecto, Inc..